As monotherapy or in combination w/ pegylated liposomal doxorubicin or dexamethasone for adult patients w/ progressive multiple myeloma who have received at least 1 prior therapy & who have already undergone or are unsuitable for haematopoietic stem cell transplantation. In combination w/ melphalan & prednisone for adult patients w/ previously untreated multiple myeloma who are not eligible for high dose chemotherapy w/ haematopoietic stem cell transplantation. In combination w/ dexamethasone, or w/ dexamethasone & thalidomide, for induction treatment of adult patients w/ previously untreated multiple myeloma who are eligible for high dose chemotherapy w/ haematopoietic stem cell transplantation. In combination w/ rituximab, cyclophosphamide, doxorubicin & prednisone adult patients w/ previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Not to be administered intrathecally. GI & haematological toxicity. Monitor platelet counts prior to each dose. Antiviral prophylaxis is recommended in case of HZV reactivation. Closely monitor for clinical & laboratory signs of active HBV infection during & following rituximab combination treatment. Monitor for neurological symptoms or signs suggestive of progressive multifocal leukoencephalopathy. Patients w/ new or worsening peripheral neuropathy; any risk factors for seizures; history of syncope receiving medicinal products known to be associated w/ hypotension or who are dehydrated due to recurrent diarrhoea or vomiting; risk factors for or existing heart disease. Discontinue in patients developing posterior reversible encephalopathy syndrome. QT-interval prolongation; pulmonary disorders; tumour lysis syndrome; potentially immunocomplex-mediated reactions. Concomitant use w/ potent CYP3A4 inhibitors, oral hypoglycemics. Renal & hepatic impairment. Pregnancy & lactation.